DNLI
HealthcareDenali Therapeutics Inc.
$16.02
$-0.25 (-1.54%)
Jan 5, 2026
Price History (1Y)
Analysis
Denali Therapeutics Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $2.50B and a significant workforce of 517 employees. The company's scale is substantial, but specific revenue figures are not available. The financial health of Denali Therapeutics Inc. reveals a challenging situation, as indicated by the absence of profitability metrics such as gross margin, operating margin, and profit margin, all registering at 0.0%. Additionally, net income (TTM) stands at -$498,744,000, while EBITDA is -$542,073,984, and free cash flow is -$249,601,872. The company has a substantial amount of cash on hand with $848.20M but also carries relatively low debt of $44.48M, resulting in a debt-to-equity ratio of 4.80. The valuation context for Denali Therapeutics Inc. highlights the company's negative earnings figures, as evidenced by a forward P/E ratio of -5.39 and an EV/EBITDA of -2.85. The absence of specific revenue growth or dividend information further complicates this assessment.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $2.50B
- P/E Ratio
- N/A
- 52-Week High
- $24.34
- 52-Week Low
- $10.57
- Avg Volume
- 1.56M
- Beta
- 1.05
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 517